Press Releases
-
Nov20
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery
-
Oct24
Cancer Genetics, Inc. Announces Strategic Transactions
Note Payment Received from Interpace Diagnostics Group, Inc. Settlement Agreement with NovellusDx
-
Oct24
Cancer Genetics Announces 1-for-30 Reverse Stock Split
RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery
-
Aug20
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery
-
Jul15
Cancer Genetics, Inc. Announces Strategic Transactions
Sale of BioPharma business to Interpace Diagnostics Group, Inc. Clinical services business acquired by siParadigm
-
May20
Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update
RUTHERFORD, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
-
Apr16
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates
RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
-
Jan31
Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
-
Jan28
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
-
Jan28
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling
